News headlines about VistaGen Therapeutics (NASDAQ:VTGN) have trended positive on Sunday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. VistaGen Therapeutics earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.7478112411258 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
VistaGen Therapeutics (NASDAQ VTGN) traded down 3.05% during mid-day trading on Friday, hitting $1.59. 42,919 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $1.66 and its 200-day moving average price is $1.85. The stock’s market cap is $14.91 million. VistaGen Therapeutics has a 12 month low of $1.53 and a 12 month high of $4.45.
VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings data on Monday, August 14th. The company reported ($0.28) earnings per share for the quarter. Equities analysts expect that VistaGen Therapeutics will post ($1.99) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://transcriptdaily.com/2017/10/08/vistagen-therapeutics-vtgn-receives-coverage-optimism-rating-of-0-26.html.
VistaGen Therapeutics Company Profile
VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA).
Receive News & Ratings for VistaGen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.